Outcome	No. of studies	No. of participants	Statistical method	Effect size	Vaccine efficacy (95% CI)
Confirmed SARS‐CoV‐2 infection after complete vaccination	N/A	N/A	N/A	N/A	N/A
Confirmed symptomatic COVID‐19 after complete vaccination	1	25,062	N/A	N/A	48.20% (31.70% to 60.90%)
Severe or critical COVID‐19 after complete vaccination	1	25,062	N/A	N/A	63.80% (0.00% to 91.70%)
All‐cause mortality	1	39,529	Risk Ratio (M‐H, Random, 95% CI)	1.33 (0.46 to 3.83)	N/A
Serious adverse events	1	39,529	Risk Ratio (M‐H, Random, 95% CI)	1.24 (0.90 to 1.71)	N/A
Systemic reactogenicity events	1	3982	Risk Ratio (M‐H, Random, 95% CI)	1.48 (1.43 to 1.53)	N/A
Any adverse event	1	3982	Risk Ratio (M‐H, Random, 95% CI)	1.42 (1.38 to 1.47)	N/A
Local reactogenicity events	1	3982	Risk Ratio (M‐H, Random, 95% CI)	3.51 (3.24 to 3.81)	N/A
CI: confidence interval; N/A: not applicable